The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | The explosion of immuno-oncology
Timothy Illidge, BSc, PhD, MRCP, FRCR, FRCPath, from University of Manchester, Manchester, UK, explains how there has been an explosion of immuno-oncology in lymphoma. He specifically mentions the use of CAR T-cell technology in inducing high response rates and durable remissions in refractory patients. In addition, drug combinations for e.g. brentuximab vedotin and nivolumab have also shown encouraging response rates in refractory patients. This interview was recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland and has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
